Trial Profile

Circulating tumor cells (CTCs) in metastatic castration-resistant prostate cancer patients treated with cabazitaxel: A Dutch Uro-Oncology Study Group side-study

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 05 Nov 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cabazitaxel (Primary) ; Budesonide; Prednisone
Indications Prostate cancer
Focus Therapeutic Use
Sponsors Sanofi

Most Recent Events

04 Oct 2016 Status changed from recruiting to active, no longer recruiting, according to the results published.
04 Oct 2016 Efficacy and safety results (n=227) published in the Clinical cancer research: an official journal of the American Association for Cancer Research.
20 Mar 2014 Not official study title and study status estimated.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com